Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1273 in children with influenza A
NCT06656026Phase 2Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlatrelvir in Influenza A (IAV) (2 arms), sponsored by Raynovent Biotech. Primary endpoint: Plasma concentrations of ZSP1273 at 5 days. Started Nov 2024; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT06656026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656026.